Maraviroc (MVC, Selzentry, ViiV Healthcare) is a small-molecule CCR5 antagonist with favorable safety, pharmacokinetic, and pharmacodynamic profiles [7, 8] that is FDA-approved for the treatment of CCR5-tropic HIV infection in both antiretroviral therapy (ART)-naïve and treatment-experienced patients [9, 10]. Here, CCR5 is linked to HIV infectious disease.